Gastrointestinal Bleeding in Antithrombotic Therapy in Patients with Coronary Heart Disease: Risk Factors, Pathogenesis and Treatment

Gastrointestinal Bleeding in Antithrombotic Therapy in Patients with Coronary Heart Disease: Risk Factors, Pathogenesis and Treatment

Aim. Description of risk factors, pathogenesis and treatment strategies of gastrointestinal bleeding (GIB) in the course of antithrombotic therapy in patients with coronary heart disease (CHD).Key points. Risk factors of GIB during antithrombotic therapy in CHD patients include: GIB, gastric and/or...

Full description

Bibliographic Details
Main Authors:	N. S. Lapina, A. A. Alekseeva, A. D. Vershinina, N. S. Khruleva, F. N. Muradova, L. Y. Koroleva
Format:	Article
Language:	Russian
Published:	Gastro LLC 2020-07-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	gastrointestinal bleeding coronary heart disease acetylsalicylic acid clopidogrel dabigatran rivaroxaban apixaban proton pump inhibitors idarucizumab
Online Access:	https://www.gastro-j.ru/jour/article/view/431

Similar Items

Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants
by: Ju Yup Lee
Published: (2018-12-01)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
by: Paolo Zappulla, et al.
Published: (2021-04-01)

GASTROINTESTINAL BLEEDING WITH THE USE OF NEW ORAL ANTICOAGULANTS: EPIDEMIOLOGY, RISK FACTORS, TREATMENT, AND PREVENTION
by: E. V. Moroz, et al.
Published: (2018-01-01)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
by: Giannandrea D, et al.
Published: (2019-05-01)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
by: Yoshinari Morimoto, et al.
Published: (2016-03-01)

DENTAL IMPLICATIONS OF THE NEW ORAL ANTICOAGULANTS
by: Cringuta Paraschiv, et al.
Published: (2016-01-01)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
by: Sié P
Published: (2016-05-01)

Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
by: James S Kalus
Published: (2013-04-01)

Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention
by: Yu. A. Karpov
Published: (2019-12-01)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
by: Angela Saviano, et al.
Published: (2022-11-01)

A Combination of Ex Vivo and In Vivo Strategies for Evaluating How Much New Oral Anticoagulants Exacerbate Experimental Intracerebral Bleeding
by: Ferreira Ferreira, et al.
Published: (2023-07-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
by: S. N. Bel'diev, et al.
Published: (2019-05-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
by: Sergey N. Bel'diev, et al.
Published: (2019-05-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
by: Sergey N. Bel'diev, et al.
Published: (2019-05-01)

Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists
by: Giancarlo Landini, et al.
Published: (2013-12-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES
by: Ya. P. Dovgalevskiy, et al.
Published: (2016-01-01)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
by: Jameel Abdulrehman, et al.
Published: (2021-07-01)

Are outpatient anticoagulation management services the wave of the future (again)?
by: Bethany Samuelson Bannow
Published: (2022-05-01)

New oral anticoagulants and cardiac safety: do we have a problem?
by: E. M. Nifontov
Published: (2018-04-01)

A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01)

IMPACT OF NON-VITAMIN K ORAL ANTI-COAGULANTS ON WARFARIN UTILISATION AND NHS BUDGET IN UK
by: Mohammed Aladul, et al.
Published: (2022-09-01)

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
by: Jamshed Dalal, et al.
Published: (2015-12-01)

Prevention of recurrent deep-vein thrombosis
by: Andrew N Nicolaides
Published: (2019-01-01)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01)

DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS
by: S. N. Bel'diev, et al.
Published: (2017-11-01)

Pharmacogenetics of new oral anticoagulants
by: Bella A. Azimova, et al.
Published: (2023-04-01)

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01)

The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
by: B. A. Tatarsky, et al.
Published: (2020-05-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016-09-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
by: Sergey Nikolaevich Bel'diev, et al.
Published: (2017-11-01)

Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows
by: Luca Masotti, et al.
Published: (2012-10-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
by: Sergey Nikolaevich Bel'diev, et al.
Published: (2017-11-01)

HOW NEW APPROACHES TO THE TREATMENT OF PULMONARY EMBOLISM AFFECT THE OUTCOME OF THE DISEASE?
by: M. Y. Gilyarov, et al.
Published: (2017-12-01)

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
by: Tomas L. Lindahl, et al.
Published: (2017-07-01)

A Study on the Effects of Dırect Factor Xa Inhibitors and Direct Thrombin Inhibitors on Human Primary Chondrocyte Cultures
by: Yasin Emre KAYA, et al.
Published: (2019-12-01)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
by: Dopsaj Violeta
Published: (2020-01-01)

Management of Patients Using Oral Anticoagulant Agent in Dental Practice
by: Özge DOĞANAY, et al.
Published: (2019-07-01)

The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy
by: Luca Masotti, et al.
Published: (2013-12-01)